QUARTERLY COMPANY INFORMATION AND DISCLOSURE STATEMENT

Rafarma Pharmaceuticals, Inc.
August 31, 2014

1) Name of the issuer and its predecessors (if any)

Rafarma Pharmaceuticals, Inc.
The result of merger of Airprotec International, Inc. 3/2002 – 10/12 and Johnston Acquisitions, Inc. 03/2002 – 10/12, previously JSN Industries until 03/2002

2) Address of the issuer's principal executive offices

Company Headquarters

203 S. Main Suite 3000
Sheridan WY 82801
+1 307 9200161
rafarma.us

3) Security Information

Trading Symbol: RAFA
Exact title and class of securities outstanding: Common
CUSIP: 75062C 100
Par or Stated Value: $.001
Total shares authorized: 300,000,000 as of August 31, 2014
Total shares outstanding: 83,866,999 as of: August 31, 2014

Preferred Share Information
Exact title and class of securities outstanding: Preferred Series "A"
CUSIP: N/A Not a listed security
Par or Stated Value: $.001
Total shares authorized: 30,000,000 as of: August 31, 2014
Total shares outstanding: 30,000,000 as of: August 31, 2014

Transfer Agent
Standard Register and Transfer
12528 S 1840 E
Draper, UT 84020
Phone: +1 801 571- 2944

Is the Transfer Agent registered under the Exchange Act?* Yes
.
List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

4) Issuance History

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

None: All shares were issued for services

B. Any jurisdictions where the offering was registered or qualified;

None

C. The number of shares offered;

N/A

D. The number of shares sold;

6,196,129 (approximate)

E. The price at which the shares were offered, and the amount actually paid to the issuer;
All shares were issued for services

No funds were received by the Issue

F. The trading status of the shares; and

3,596,000 were issued unrestricted 2,600,129 were rstricted

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

Yes

5) Financial Statements

See interim Financial Statements dated August 31, 2014 published on the OTC Markets website under Rafarma Pharmaceuticals, Inc. : filings and disclosures, herein incorporated by reference.

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. a description of the issuer's business operations;

The Company acquired the ownership of the distributed pre-tax revenues of "ZAO Rafarma" a manufacturer of generic pharmaceuticals and proprietary medications. The company has no ownership managerial rights or

control over “ZAO Rafarma” and is only the beneficial owner of distributed profits, much as a non-controlling member of an LLC.

B. Date and State (or Jurisdiction) of Incorporation:

The Company was incorporated in Nevada on May 26, 2004

C. the issuer’s primary and secondary SIC Codes;

Primary SIC Code: 283407 – Laboratories – Pharmaceuticals
Secondary SIC Code: 283496 – Pharmaceutical Preparation
Other Sic Code: 512203 – Pharmaceutical Products - Wholesale

D. the issuer’s fiscal year end date;

November 30

E. principal products or services, and their markets;

The Company acquired the ownership of the distributed pre-tax revenues of “ZAO Rafarma” a manufacturer of generic pharmaceuticals and proprietary medications. The company has no ownership managerial rights or control over “ZAO Rafarma” and is only the beneficial owner of distributed profits, much as a non-controlling member of an LLC.

7) Describe the Issuer’s Facilities

The Company maintains office space at 24 KKutuzovsky prospect, Moscow, 121151, Russia.

8) Officers, Directors, and Control Persons

Bruno Horn, Chairman, President
24 KKutuzovsky prospect, Moscow, 121151, Russia.

Billy Bailey: Vice President, Director
24 KKutuzovsky prospect, Moscow, 121151, Russia.

Cristopher Corwin, Director
24 KKutuzovsky prospect, Moscow, 121151, Russia.

B. Legal/Disciplinary History.

None

C. Beneficial Shareholders

Nashe Pravo
Mozhaiskoye Shosse 2-466
12137 Moscow, Russia
Controls 8% of the Common stock
Control Person: George Chernof

Vladiimir Bonder
24 KKutuzovsky prospect, Moscow, 121151, Russia.
Controls 12% of the Preferred Series “A” stock

Bruno Horn
24 KKutuzovsky prospect, Moscow, 121151, Russia.
Controls 70% of the Preferred Series “A” stock

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

None

10) Issuer Certification

I, Bill Bailey certify that:

1. I have reviewed this quarterly report of Rafarma Pharmaceutical, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 31, 2014

/s/ Billy Bailey
Vice President, Director

I, Christopher Corwin certify that:

1. I have reviewed this quarterly report of Rafarma Pharmaceutical, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 31, 2014

/s/ Cristopher Corwin
Director